As an approved medicinal product and reportedly an abused substance that have been associated with death and "considered to be a factor...of impaired driving, sexual assault, and other violent crimes", triazolam is controlled at the same level (Level III) 
Introduction
Triazolam is a potent and short-acting hypnotic. As a relatively new addition to the benzodiazepine family, it has changed the "safe" drugs perception of benzodiazepines (1) . Deaths involving this drug have been reported by toxicologists from Canada (2), the U.K. (3), Denmark (1), Japan (4) , and the U.S. (5) .
Numerous studies have focused on the effects (6), pharmacokinetics (7), deposition (5, 8) , and postmortem changes (9) of triazolam. Other studies are concerned with modern analytical approaches. For example, Fraser and Meatherall (10) studied the effectiveness of five immunoassays as screening methodologies for gas chromatography-mass spectrometry (GC-MS) analysis; sample preparation procedures were explored by other workers (11) (12) (13) ; the latest quantitation approach using an isotopically labeled analogue as the internal standard has also been applied to the quantiation of triazolam (12) .
Triazolam is reportedly "frequently abused in New Zealand and is considered to be a factor in some cases of impaired driving, sexual assault, and other violent crimes" (12) . In Taiwan, triazolam is approved for medicinal use and controlled at the same level (Level III) as flunitrazepam. Alleged misuses of this substance have also been associated with case specimens submitted to this laboratory. With these concerns in mind, we have referred to literature references to develop protocols suitable for the analysis of various biological specimens routinely encountered in our laboratory. We have also conducted a very limited number of studies to verify whether the excretion profile of this drug's major metabolite (cr triazolam) in the local population is parallel to those reported from other parts of the world. Because only trace amounts of the parent drug appear in the urine, triazolam is not monitored in this study.
Materials and Methods
Standards, reagents, chemicals, and specimens cr and (z-hydroxytriazolam-d4 standards in methanol (100 pg/mL) were purchased from Cerilliant (Austin, TX). Helixpomatia 13- 
Sample preparation
Two milliliters of urine was spiked with 50 1JL of ~-hydroxytriazolam-d4 (2 IJg/mL) as internal standard. For hydrolysis (not performed when determining free (x-hydroxytriazolam), 50 IJL of 2M sodium acetate buffer (pH 4.5) and 100 1JL of [~-glucuronidase were added; the mixture was then incubated for 2 h at 56~ (14) . (A literature search on enzymatic hydrolysis of benzodiazepines results in 12 references with 9 performing the incubation at 56~ and 3 at _ 37--45~ Hydrolysis products were further processed by liquid-liquid or solid-phase extraction. For liquid-liquid extraction, I mL of Na2COJ NaHCO3 buffer (pH 9.5) and 5 mL of ethyl acetate were added. The mixture was slowly shaken on a mechanical shaker for 5 rain and then centrifuged for 5 rain. The organic layer (top) was quantitatively transferred to a clean screw-top tube and dried under a stream of nitrogen at 50~
For solid-phase extraction, the manufacturers' instructions were followed. ~pically, the hydrolysis product was allowed to cool to room temperature, then adjusted to pH 6.0 with phosphate buffer (1 mL). Solid-phase extraction columns were first treated with I mL methanol, followed by I mL phosphate buffer (pI-I 6.0). Hydrolysis products (or specimens when determining free (z-hydroxytriazolam) were applied to the columns requiring at least 2 min to flow through. The columns were then washed with 0.]M acetic acid (1 mL) and methanol (1 mL) and dried for I min. The analyte was eluted with i mL mixture of ethyl acetate, methanol, and ammonium hydroxide (4:1:0.1, v/v). The resulting extracts were dried under a stream of nitrogen at 50~
For derivatization, 35 1JL ethyl acetate and 35 IJL MSTFA were added to the residue in the screw-top tube prepared. The tube was capped and vortex mixed for 20 s and then heated at 100~ for 15 min. The reaction mixture was allowed to cool to room temperature prior to GC-MS analysis.
GC-MS analysis
An Agilent 6890 GC-5973N mass selective detector (GC-MSD) system was used for this study. The GC was equipped with a 30-m Hewlett-Packard (Andover, MA) 5MS fused silica capillary column (0.25-ram i.d., 0.25-IJm film thickness). The injector and interface temperature were maintained at 260 and 280~ respectively. Oven temperature was held at 150~ for 1 rain, then programmed to 300~ at 20~ and held at the final temperature for 1 min. The following parameters were used for injecting samples into the GC-MSD system: sample size, 2 t~L; injection mode, splitless; and injector purge-off duration, 1 min.
Mass range adapted for collecting full-scan mass spectra was m/z 50-550. Typical mass spectra of the analyte and the internal standards are shown in Figure 1 . Based on ion intensity data of full-scan mass spectra, the following ions were evaluated and adapted to designate TMS-derivatized analyte and internal standard: m/z 415, 417, and 430 (for a-hydroxytriazolam) and 419, 421, and 434 (for a-hydroxytriazolam-d4). The first ion 
ng/mL) calibration protocol. Example chromatograms derived from the adapted selected ion monitoring protocol are shown in Figure 2 . 
Results and Discussion
With the limited number of specimens requiring testing for triazolam, this laboratory has not placed emphasis on the evaluation of newer immunoassays that may be most effective for preliminary testing of this drug. Analytical parameters hereby discussed are mainly on GC-MS and related sample preparation protocol. However, specimens collected from two cases to study excretion-profiles were also tested by TDx. These data will be commented on in a later section.
Analytical parameters
Recovery. One liquid-liquid and three solid-phase extraction protocols were evaluated for their efficiencies in the recovery of free a-hydroxytriazolam from urine specimens. Evaluations were performed using drug-free urine fortified with 10-200 ng/mL a-hydroxytriazolam, and the samples were processed with and without the hydrolysis step. The hydrolysis protocol was included in the evaluation process to determine whether reagents, reaction products, and the conditions associated with the hydrolysis will affect recovery. Excellent recoveries (Table I) were observed from the liquid-liquid extraction protocol, which was then used for the remainder of this study. It is interesting to note that recoveries resulting from the use of all three solidphase sorbents are very poor (< 30%), in contrast to their successful applications to the extraction of 7-aminoflunitrazepam (> 90% as routinely observed in our laboratory).
Limits of quantitation (LOQ) and detection (LOD) and calibration.
Two series of standards ranging from 0.05 to 2.0 and 1.0 to 20 ng/mL r were used for the determination of the method's LOD and LOQ. Commonly used criteria were adapted for defining LOD and LOQ. Specifically, LOD is defined as the lowest concentration at which the monitored ion ratios are within _+ 20% of that observed for the 50 ng/mL standard, and LOQ is defined as the lowest concentration at which the observed concentration is within + 20% of the targeted value.
Based on data shown in Table II , the protocol's LOD and LOQ were set at 0.05 and 0.10 ng/mL, allowing the determination of free c~-hydroxytriazolam at lower concentration levels than totalc~-hydroxytriazolam (see Excretion profile section). Typical calibrations covers two different concentration ranges (0-20 ng/mL and 0-200 ng/mL) for the analysis of free ~-hydroxytriazolam (without the addition of the enzyme 12.6 and the incubation step) and the analysis of Precision and accuracy. Typical intra-and interday precision and accuracy data obtained from standards at the 10-200 ng/mL range are shown in Table III . Together with the recovery and calibration data shown here, we are confident that the protocol hereby established can provide reliable data under routine analytical settings.
~-Hydroxytriazolam excretion profile
Listed in Tables IV and V are urinary excretion profiles of two individuals following the intake of 0.25 mg triazolam (Halcion). The concentrations of free and total c~-hydroxytriazolam derived from GC-MS analysis are plotted in Figure 3 , and the quantity of total (~-hydroxytriazolam collected between collection points are plotted in Figure 4 . These data indicate urinary excretions are equivalent to 32.2% (0.6% in free and 31.6% in conjugated forms) and 57.2% (0.36% in free and 56.8% in conjugated forms) in Case A and Case B, respectively. A Canadian study on antemortem (15) and a U.S. study on postmortem specimens (5) have also reported urinary excretion of ~-hydroxytriazolam predominately in the conjugated form.
Because the data listed in the last columns of Tables IV and V reflect GC-MS detection of total ~-hydroxytriazolam, whereas the TDx data listed in these two tables represent the sum of this immunoassay's responses to the free and the conjugated forms of (x-hydroxytriazolam and related metabolites, we are curious about the relationship between these two sets of data. Thus, these data pairs are plotted in Figure 5 similar to a Cannabis study reported in the literature (16) . The resulting correlation coefficient indicates that the TDx and the GC-MS data are closely related. It is interesting to note that the apparent TDx (~-hydroxytriazolam concentrations are lower than the corresponding GC-MS c~-hydroxytriazolam concentrations. This is an indication that conjugated (~-hydroxytriazolam has lower cross-reactivity toward the antibody than the calibration standard (nordiazepam) adapted by TDx.
The resulting correlation parameters further indicate, in the absence of other cross-reacting compounds, TDx can be a very effective immunoassay in detecting the presence of (x-hydroxytriazolam in its conjugated forms and in predicting the total concentration of c~-hydroxytriazolam. It should be noted, however, since the cross-reacting characteristics of other related compounds (such as other benzodiazepams and their metabolites) have not been evaluated in this study, the effect of these compounds on TDx's effectiveness in serving as a preliminary test methodology for detecting triazolam exposure is not known.
Total ~-hydroxytriazolam concentration data listed in the last columns and the corresponding collection times of these samples listed in the second columns of Tables IV and V are further used to estimate the detection time following the ingestion of 0.25 mg of triazolam by taking one oral dose of Halcion. These data indicate 1. data observed from these two cases are rather consistent and 2. using 10 ng/mL total cr zolam concentration as the cutoff, oral intake of 0.25 mg triazolam can be detected for a duration of approximately 24 h. Using 1 ng/mL total (z-hydroxytriazolam as the cutoff, the detection time can be extended to 48 h.
Conclusions
This study has established an effective procedure for the analysis of free and conjugated cr capable of detecting triazolam (0.25 mg) ingestion for 24 to 48 h using 10 and 1 ng/mL total (z-hydroxytriazolam as the cutoffs, respectively. TDx and GC-MS data derived from urine specimens collected under controlled environment exhibit excellent correlation. Analytical data clearly indicate the excretion of ~-hydroxytriazolam in urine is predominately in its conjugated forms. Excretion profiles of free and conjugated cr azolam observed in the two cases from local population are comparable.
